Journal: International Journal of Molecular Sciences

Article Title: G9a Knockdown Suppresses Cancer Aggressiveness by Facilitating Smad Protein Phosphorylation through Increasing BMP5 Expression in Luminal A Type Breast Cancer

doi: 10.3390/ijms23020589

Figure Lengend Snippet: G9a knockdown may lead to increase in BMP5 expression. ( A ) Regulatory factors suppressing tumor aggressiveness were identified by using microarray analysis. ( B ) Expression levels for each gene were compared (ratios between gene expression levels of non-silencing control). In two G9a knockdown cells (shG9a #1 and shG9a #2), expression levels for each gene were compared to those of non-silencing control. Then the most upregulated and downregulated genes were screened. ( C ) G9a knockdown cells showed increase in BMP5 expression. ( D ) Reduced G9a occupancy was found at the BMP5 promoter region. G9a knockdown cells also showed decreased H3K9me2 occupancy at the promoter region of BMP5. p values were calculated using ANOVA. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Article Snippet: Western blot analysis was performed with antibodies specific for the following proteins: G9a (#229455, Abcam, Cambridge, MA, USA), E-cadherin (#3195S, Cell Signaling, Boston, MA, USA), β-catenin (#8480P, Cell Signaling, Boston, MA, USA), ZO-1 (#5406P, Cell signaling, Boston, MA, USA), PARP (#9542S, Cell signaling, Boston, MA, USA), Caspase-7 (#9492S, Cell signaling, Boston, MA, USA), BMP5 (#13253-1-AP, Proteintech, Chicago, IL, USA), p -Smad1/5/9 (#13820T, Cell Signaling, Boston, MA, USA), p -Smad1/5 (#9516T, Cell Signaling, Boston, MA, USA), Smad1 (#6944T, Cell Signaling, Boston, MA, USA) and β-actin.

Techniques: Knockdown, Expressing, Microarray, Gene Expression, Control

Journal: International Journal of Molecular Sciences

Article Title: G9a Knockdown Suppresses Cancer Aggressiveness by Facilitating Smad Protein Phosphorylation through Increasing BMP5 Expression in Luminal A Type Breast Cancer

doi: 10.3390/ijms23020589

Figure Lengend Snippet: BMP5 contributes to reduce migration and invasion abilities of tumor cells. ( A ) Low BMP5 expression is associated with poor survival outcomes of breast cancer patients. ( B ) Patients with stage 3 disease showed higher BMP5 levels than those of stage 2 patients. ( C , D ) Migration/invasion abilities were decreased by treatment of recombinant BMP5; however, the capabilities were enhanced following BMP5 downregulation. p values were calculated using ANOVA. * p < 0.05, ** p < 0.01, **** p < 0.0001.

Article Snippet: Western blot analysis was performed with antibodies specific for the following proteins: G9a (#229455, Abcam, Cambridge, MA, USA), E-cadherin (#3195S, Cell Signaling, Boston, MA, USA), β-catenin (#8480P, Cell Signaling, Boston, MA, USA), ZO-1 (#5406P, Cell signaling, Boston, MA, USA), PARP (#9542S, Cell signaling, Boston, MA, USA), Caspase-7 (#9492S, Cell signaling, Boston, MA, USA), BMP5 (#13253-1-AP, Proteintech, Chicago, IL, USA), p -Smad1/5/9 (#13820T, Cell Signaling, Boston, MA, USA), p -Smad1/5 (#9516T, Cell Signaling, Boston, MA, USA), Smad1 (#6944T, Cell Signaling, Boston, MA, USA) and β-actin.

Techniques: Migration, Expressing, Recombinant

Journal: International Journal of Molecular Sciences

Article Title: G9a Knockdown Suppresses Cancer Aggressiveness by Facilitating Smad Protein Phosphorylation through Increasing BMP5 Expression in Luminal A Type Breast Cancer

doi: 10.3390/ijms23020589

Figure Lengend Snippet: G9a knockdown facilitates Smad protein phosphorylation via BMP5 activation. ( A , B ) G9a-knockdown-induced increase in BMP5 expression had no effect on the total level of either Smad1 or Smad5. G9a knockdown increased phosphorylation of Smad1/5/9. ( C ) ICC demonstrated that nuclear translocation of pSmad1/5/9 was increased in G9a-depleted MCF7 cells. ( D ) Similar tendency was found after treatment of recombinant BMP5. p values were calculated using ANOVA. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, ns = not significant.

Article Snippet: Western blot analysis was performed with antibodies specific for the following proteins: G9a (#229455, Abcam, Cambridge, MA, USA), E-cadherin (#3195S, Cell Signaling, Boston, MA, USA), β-catenin (#8480P, Cell Signaling, Boston, MA, USA), ZO-1 (#5406P, Cell signaling, Boston, MA, USA), PARP (#9542S, Cell signaling, Boston, MA, USA), Caspase-7 (#9492S, Cell signaling, Boston, MA, USA), BMP5 (#13253-1-AP, Proteintech, Chicago, IL, USA), p -Smad1/5/9 (#13820T, Cell Signaling, Boston, MA, USA), p -Smad1/5 (#9516T, Cell Signaling, Boston, MA, USA), Smad1 (#6944T, Cell Signaling, Boston, MA, USA) and β-actin.

Techniques: Knockdown, Phospho-proteomics, Activation Assay, Expressing, Translocation Assay, Recombinant

Journal: Nature Communications

Article Title: Bone marrow-derived epithelial cells and hair follicle stem cells contribute to development of chronic cutaneous neoplasms

doi: 10.1038/s41467-018-07688-8

Figure Lengend Snippet: CD34 − , CD44 + BMCs express keratin after BMC/KC co-culture and BMP5 treatment. a , b All adherent BMCs are CD34-negative and CD44-positive. c , e A sub set of adherent BMCs are pan-keratin-immunoreactive (arrowheads) after 7days of BMC/KC co-culture (keratin-positive BMCs in white boxes are magnified and merged with phase image). d Pan-keratin-immunoreactive BMC (arrowhead) identified 10 days after BMP5 treatment. f K14-immunoreactive cells (arrowheads) 10 days after BMP5 treatment (white box area is magnified). g Histogram of number of keratin-expressing BMCs; BMCs without treatment, BMC/KC co-culture (pan-keratin-positive BMCs, gray bar) and BMP5 treatment (K14-positive BMCs, black bar), pan-keratin- and K14-immunoreactive BMCs are detected in KC co-cultured and BMP5-treated BMCs, but no keratin-positive cells are detected in treatment controls ( n = 3, 3 different culture groups, 3 male and 3 female mice in each group; P < 0.017 as determined by Student’s t -test, mean ± s.d.) h Q-RT-PCR results show the relative level of K14 expression detected from positive (primary KCs and Tg.AC, a KC cancer cell-line) and negative (Swiss mouse 3T3 cell-line and primary BMCs) control groups, and experimental (BMC/KC co-culture and BMP5 treatment) groups. The expression levels were normalized to GAPDH expression levels, and expression mean values were converted into fold-change gene expression. Final values were normalized with log 2 transformation. ( n = 3, P < 4.81 × 10E−12 as determined by Fisher’s ANOVA method, mean ± s.d.). *White scale bar, 50 µm; Red scale bar, 200 µm

Article Snippet: For BMP5 (R&D systems, Minneapolis, MN; Cat# 6176-BM/CF) treatment, mesenchymal stem cell medium was changed every three days for 10 days, and BMP5 (50 ng/ml) was added immediately after changing medium (Supplementary Figure ).

Techniques: Co-Culture Assay, Expressing, Cell Culture, Reverse Transcription Polymerase Chain Reaction, Control, Gene Expression, Transformation Assay

Journal: Cancers

Article Title: Exploring Spatial Heterogeneity of Immune Cells in Nasopharyngeal Cancer.

doi: 10.3390/cancers15072165

Figure Lengend Snippet: Figure 1. Differential expression profiles in CD45+ segments from ‘immune-rich cancer cell islets’ and ‘surrounding stromal leukocyte’ regions in NPC. (a) AOIs were generated based on cell expression of the morphological markers CD45 (red), PanCK (cyan), and CD8 (magenta) from the ROIs, and the collected oligonucleotides were quantified using the GeoMx® DSP system. (b) Biplot principal component analysis showing ROI segments (AOIs) as well as protein markers on the first and second components from ‘immune-rich cancer cell islets’ and ‘surrounding stromal leukocyte’ regions. (c) Heatmap demonstrating DE proteins between ‘immune-rich cancer cell islets’ and ‘surrounding stromal leukocyte’ regions (Mann–Whitney test, p-value < 0.05). (d) Twenty DE proteins’ correlation map (Pearson’s correlation, significance taken at |r| > 0.7, p-value < 0.05).

Article Snippet: Glass slides containing 5 μm sections of the FFPE TMAs were stained with DNA stain (SYTOTM 13 Green Fluorescent Nucleic Acid Stain, Invitrogen, Waltham, MA, USA), fluorescently labelled antibodies against CD8 (CD8-AF666/Cy5, clone OTI3H6, Origene, Rockville, MD, USA), PanCK (pan-Cytokeratin-AF568/Cy3, clone AE1 + AE3, Novus Biologicals, Littleton, CO, USA), and CD45 (CD45-AF615/Texas Red, clone 2B11 + PD7/26, Novus Biologicals, Eaglewood, CO, USA) (Figure S1 and Table 1).

Techniques: Quantitative Proteomics, Generated, Expressing, MANN-WHITNEY